Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

ented PFS data, further define satraplatin's clinical profile as a potential second-line treatment option in metastatic HRPC.

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. Overall survival data are expected to be available later this year. Pharmion expects to complete the Marketing Authorization Application (MAA) for satraplatin for Europe in the second quarter of 2007. GPC Biotech recently completed the New Drug Application (NDA) submission for satraplatin to the U.S. Food and Drug Administration (FDA).

Safety findings were consistent with previous clinical studies involving satraplatin. The most common adverse reactions consisted of myelosuppression (bone marrow functions): Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14 percent had leucopenia and 21 percent had neutropenia. Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Five percent or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue, grade 3 or 4 infections and pulmonary/respiratory grade 3 or 4 toxicities.

About Prostate Cancer

Prostate cancer is the most common cancer among men in the U.S. and Europe. Approximately 219,000 men in the U.S. are expected to be diagnosed with the disease in 2007 and over 27,000 men are expected to die from the disease. In the European Union, over 200,000 new cases are expected to be diagnosed, and over 60,000 patients are expected to die each year. Since the incidence of prostate cancer increases with age, the aging of the overall population is expected to further increase the number of prostate cancer patients.

Most patients diagnosed with prostate cancer initially receiv
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:11/21/2014)...  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, announced today that it will increase ... strong launch of Edwards Lifesciences Foundation,s new charitable initiative, ... global communities where its employees live and work. ... exceed $8 million, including more than $7 million in ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
(Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals ... the first U.S. commercial producer of Molybdenum-99 (Mo-99), is ... with INVAP to design its Medical Isotope ... Mo-99 is the parent isotope of Technetium-99, which ... worldwide. In 2012, Congress passed legislation making it a ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
(Date:11/23/2014)... 2014 Wright & Schulte LLC recently ... and West Virginia residents who allege that they developed ... due to drinking C8 contaminated water released by ... According to the C8 complaints, the plaintiffs were exposed ... lived in at least one of the six water ...
(Date:11/22/2014)... Every year AlignLife clinics nationwide team together to ... in the Greenville, SC area in 2014 and has ... Simpsonville will be partnering with the 5 other ... Drive. These six offices came together to decide on ... toy drive. With so many amazing organizations to choose ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress company, has ... Customers can buy new dresses at its online shop ... website. , As a matter of fact, PrettyTailor specializes ... provides four types of wedding outfits, including bridesmaid dresses, ... It also provides a variety of occasion dresses, such ...
(Date:11/22/2014)... November 23, 2014 Recently, Locks-Magnetic.com ... introduced a new promotion of mag locks for glass ... an attracting discount on these fresh products. Customers can ... locks for glass doors are in excellent performance. Customers ... the website as soon as possible. They also ...
(Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
Breaking Medicine News(10 mins):Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... children are far more likely to receive cranial computed ... head trauma than are African-American or Hispanic children, a ... The study findings do not indicate that CT scans ... researchers said. Rather, they suggest that white children may ...
... -- Fewer than half of U.S. children injured in car ... minority children had the lowest rates of seat-belt use, a ... involving nearly 40,000 children under age 16 and found that ... had the lowest rates of seat-belt use. The overall ...
... BOSTON Sports-related knee injuries in children and adolescents seem ... the Children,s Hospital of Philadelphia noted a more than 400 ... last decade, according to new research presented on Sunday, Oct. ... and Exhibition in Boston. In "Knee Injuries In ...
... Maternal Health Advocate Christy Turlington Burns will speak at ... Child Health meeting at the AAP National Conference & ... p.m. ET. Ms. Turlington Burns is the founder of ... 2010 to increase public awareness of and support for ...
... treatment beyond two days was linked to an ... formation; longer hospitalization; increased costs; and more rarely, ... at the American Academy of Pediatrics (AAP) National ... Opportunities in the Treatment of Pediatric Appendicitis," researchers ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Oct. 14 ... recent years by becoming more and more personalized. Not ... tumors and cancer cells inside that patient. New tests ... factors are driving each individual woman,s type of cancer, and ...
Cached Medicine News:Health News:White children far more likely to receive CT scans than Hispanic, African-American children 2Health News:Fewer Than Half of Kids Hurt in Car Crashes Wearing Seat Belts 2Health News:Knee injuries on the rise in child and adolescent athletes 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Genetic Profiling Adds New Dimension to Breast Cancer Treatment 2Health News:Genetic Profiling Adds New Dimension to Breast Cancer Treatment 3
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile...
Reservoir, High Profile, Single Well, 12 Row, Pyramid Bottom Available Sterile...
... applications or for use in an automated ... eight-port disposable manifold provides greater ease, speed, ... The StatMatic II can be connected to ... completely fill a microplate with one-handed operation ...
... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
Medicine Products: